Teva and Regeneron report positive Phase 3 results for Fasinumab in osteoarthritis pain management

Teva Pharmaceutical Industries and Regeneron Pharmaceuticals have announced successful outcomes from their phase 3 study of fasinumab, a nerve growth factor (NGF) antibody, in patients ... Read More